



ANDA 204086

**ANDA APPROVAL**

Hospira, Inc.  
275 North Field Drive  
Dept. 0389, Bldg. H2-2  
Lake Forest, IL 60045  
Attention: Pamela Cabrera  
Associate, Global Regulatory Affairs

Dear Madam:

This letter is in reference to your abbreviated new drug application (ANDA) submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial (single-dose vials).

Reference is also made to the complete response letter issued by this office on March 27, 2015, and to your amendments dated September 11 and November 18, 2015; and April 20, April 25, and May 11, 2016.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the **ANDA is approved**, effective on the date of this letter. The Office of Bioequivalence has determined your Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Treanda for Injection, 25 mg/vial and 100 mg/vial, of Cephalon, Inc. (Cephalon).

The RLD upon which you have based your ANDA, Cephalon's Treanda for Injection, 25 mg/vial and 100 mg/vial, is subject to periods of patent protection. The following patents and expiration dates (with pediatric exclusivity added) are currently listed in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
8,436,190 (the '190 patent)	April 26, 2031
8,445,524 (the '524 patent)	September 26, 2029
8,609,863 (the '863 patent)	July 12, 2026
8,669,279 (the '279 patent)	September 26, 2029
8,791,270 (the '270 patent)	July 12, 2026
8,883,836 (the '836 patent)	September 26, 2029
8,895,756 (the '756 patent)	July 12, 2026

Your ANDA contains paragraph IV certifications to the '190, '836 and '756 patents as well as any claims of the '524, '279, '270 and '836 patents related to the drug substance, drug product, and method-of-use claims associated with Chronic Lymphocytic Leukemia, under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial, under this ANDA. You have notified the agency that Hospira, Inc. (Hospira) complied with the requirements of section 505(j)(2)(B) of the FD&C Act, and that litigation was initiated against Hospira for infringement of the '190 and '524 patents within the statutory 45-day period in the United States District Court for the District Court of Delaware [Cephalon, Inc., v. Hospira, Inc., Civil Action No. 1:13-cv-02094-GMS]; for infringement of the '270 [Cephalon, Inc., v. Hospira, Inc., Civil Action No. 1:14-cv-01242-UNA]; and for infringement of the '863, '279, '836, and '756 patents [Cephalon, Inc., v. Hospira, Inc., et al., Civil Action No. 1:13-cv-02046-GMS].<sup>1</sup> The individual suits were consolidated [Bendamustine Consolidated Cases, Civil Action No. 1:13-cv-02046-GMS]. You also have notified that this case was dismissed with respect to the '524, '279, and '836 patents. Although this litigation remains ongoing with respect to the remaining patents, the 30-month period identified in section 505(j)(5)(B)(iii) of the FD&C Act, during which time FDA was precluded from approving your ANDA, has expired.

Your ANDA also contains a statement under section 505(j)(2)(A)(viii) of the FD&C Act indicating that certain claims within the '524, '279, '270, and '836 patents are method-of-use patent claims, and that you are not seeking approval of any use claims of these patents associated with Non-Hodgkins Lymphoma (U-1402 and U-1542) under this ANDA.

With respect to 180-day generic drug exclusivity, we note that Hospira was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. Therefore, with this approval, Hospira may be eligible for 180 days of shared generic drug exclusivity for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. The Agency notes that Hospira failed to obtain tentative approval of this ANDA within 30 months after the date on which the ANDA was filed. See section 505(j)(5)(D)(i)(IV) of the FD&C Act (forfeiture of exclusivity for failure to obtain tentative approval). The Agency is not, however, making a formal determination at this time of Hospira's eligibility for 180-day generic drug exclusivity.

At least one first applicant remains eligible for 180 days of generic drug exclusivity for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, will begin to run from the date of the commercial marketing by any first applicant, as identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA informing the Agency of the date you begin commercial marketing.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

---

<sup>1</sup> The agency notes that the '279, '270, '836, '863 and '756 patents were submitted to the agency after submission of your ANDA and therefore, litigation, if any, with respect to those patents creates no statutory stay of approval.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL

files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

**William P.  
Rickman -S**

 Digitally signed by William P. Rickman -S  
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA,  
ou=People,  
0.9.2342.19200300.100.1.1=1300043242,  
cn=William P. Rickman -S  
Date: 2016.05.20 10:27:03 -04'00'

For Carol A. Holquist, R.Ph.

Acting Deputy Director

Office of Regulatory Operations

Office of Generic Drugs

Center for Drug Evaluation and Research